Transforming Growth Factor-β-Activated Kinase 1 (TAK1) Alleviates Inflammatory Joint Pain in Osteoarthritis and Gouty Arthritis Preclinical Models

References

• Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett. 2004;361(1–3):184–187. doi:10.1016/j.neulet.2003.12.007
   PubMed Web of Science ®Google Scholar
• Vanderwall AG, Milligan ED. Cytokines in pain: harnessing endogenous anti-inflammatory signaling for improved pain management. Front Immunol. 2019;10:3009. doi:10.3389/fimmu.2019.03009
   PubMed Web of Science ®Google Scholar
• Lopes EBP, Filiberti A, Husain SA, Humphrey MB. Immune contributions to osteoarthritis. Curr Osteoporos Rep. 2017;15(6):593–600. doi:10.1007/s11914-017-0411-y
   PubMed Web of Science ®Google Scholar
• de Lange-Brokaar BJ, Ioan-Facsinay A, van Osch GJVM, et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthritis Cartilage. 2012;20(12):1484–1499. doi:10.1016/j.joca.2012.08.027
   PubMed Web of Science ®Google Scholar
• Wieseler-Frank J, Maier SF, Watkins LR. Central proinflammatory cytokines and pain enhancement. Neurosignals. 2005;14:166–174. doi:10.1159/000087655
   PubMedGoogle Scholar
• Matsuda M, Huh Y, Ji RR. Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain. J Anesth. 2019;33(1):131–139. doi:10.1007/s00540-018-2579-4
   PubMed Web of Science ®Google Scholar
• Obata K, Noguchi K. MAPK activation in nociceptive neurons and pain hypersensitivity. Life Sci. 2004;74(21):2643–2653. doi:10.1016/j.lfs.2004.01.007
   PubMed Web of Science ®Google Scholar
• Arra M, Abu-Amer Y. Cross-talk of inflammation and chondrocyte intracellular metabolism in osteoarthritis. Osteoarthritis Cartilage. 2023;31(8):1012–1021. doi:10.1016/j.joca.2023.04.003
   PubMed Web of Science ®Google Scholar
• Konttinen YT, Sillat T, Barreto G, Ainola M, Nordstrom DC. Osteoarthritis as an autoinflammatory disease caused by chondrocyte-mediated inflammatory responses. Arthritis Rheum. 2012;64(3):613–616. doi:10.1002/art.33451
   PubMed Web of Science ®Google Scholar
• Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2011;7(1):33–42. doi:10.1038/nrrheum.2010.196
   PubMed Web of Science ®Google Scholar
• Shi M, Luo J, Ding L, Duan L. Spontaneous resolution of acute gout: mechanisms and therapeutic targets. RMD Open. 2023;9(3):e003586. doi:10.1136/rmdopen-2023-003586
   PubMed Web of Science ®Google Scholar
• ILARIS® (canakinumab) injection [Package Insert], East Hanover, NJ: Novartis, 2009.
   Google Scholar
• Schieker M, Conaghan PG, Mindeholm L, et al. Effects of interleukin-1beta inhibition on incident hip and knee replacement: exploratory analyses from a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2020;173(7):509–515. doi:10.7326/M20-0527
   PubMed Web of Science ®Google Scholar
• Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American college of rheumatology/arthritis foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220–233. doi:10.1002/art.41142
   PubMed Web of Science ®Google Scholar
• FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of rheumatology guideline for the management of gout. Arthritis Care Res. 2020;72(6):744–760. doi:10.1002/acr.24180
   PubMed Web of Science ®Google Scholar
• Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11(2):81s–110s. doi:10.18433/J3T886
   PubMed Web of Science ®Google Scholar
• Romsing J, Moiniche S. A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain. Acta Anaesthesiol Scand. 2004;48(5):525–546. doi:10.1111/j.0001-5172.2004.00379.x
   PubMed Web of Science ®Google Scholar
• Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther. 2013;15(Suppl S3):2. doi:10.1186/ar4174
   Google Scholar
• Jang Y, Kim M, Hwang SW. Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception. J Neuroinflammation. 2020;17(1):30. doi:10.1186/s12974-020-1703-1
   PubMed Web of Science ®Google Scholar
• Burian M, Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther. 2005;107(2):139–154. doi:10.1016/j.pharmthera.2005.02.004
   PubMed Web of Science ®Google Scholar
• Gallelli L, Galasso O, Falcone D, et al. The effects of nonsteroidal anti-inflammatory drugs on clinical outcomes, synovial fluid cytokine concentration and signal transduction pathways in knee osteoarthritis. A randomized open label trial. Osteoarthritis Cartilage. 2013;21(9):1400–1408. doi:10.1016/j.joca.2013.06.026
   PubMed Web of Science ®Google Scholar
• Machado GC, Abdel-Shaheed C, Underwood M, Day RO. Non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain. BMJ. 2021;372:n104. doi:10.1136/bmj.n104
   PubMedGoogle Scholar
• da Costa BR, Pereira TV, Saadat P, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and Hip osteoarthritis: network meta-analysis. BMJ. 2021;375:n2321. doi:10.1136/bmj.n2321
   PubMed Web of Science ®Google Scholar
• van den Driest JJ, Schiphof D, de Wilde M, et al. Opioid prescriptions in patients with osteoarthritis: a population-based cohort study. Rheumatology. 2020;59(9):2462–2470. doi:10.1093/rheumatology/kez646
   PubMed Web of Science ®Google Scholar
• Nadeau SE, Wu JK, Lawhern RA. Opioids and chronic pain: an analytic review of the clinical evidence. Front Pain Res. 2021;2:721357. doi:10.3389/fpain.2021.721357
   Google Scholar
• Helmerhorst GT, Teunis T, Janssen SJ, Ring D. An epidemic of the use, misuse and overdose of opioids and deaths due to overdose, in the United States and Canada: is Europe next? Bone Joint J. 2017;99(7):856–864. doi:10.1302/0301-620X.99B7.BJJ-2016-1350.R1
   PubMedGoogle Scholar
• Koh HK. Community-based prevention and strategies for the opioid crisis. JAMA. 2017;318(11):993–994. doi:10.1001/jama.2017.13767
   PubMed Web of Science ®Google Scholar
• Scarneo SA, Mansourati A, Eibschutz LS, et al. Genetic and pharmacological validation of TAK1 inhibition in macrophages as a therapeutic strategy to effectively inhibit TNF secretion. Sci Rep. 2018;8(1):17058. doi:10.1038/s41598-018-35189-7
   PubMedGoogle Scholar
• Scarneo SA, Eibschutz LS, Bendele PJ, et al. Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. Arthritis Res Ther. 2019;21(1):292. doi:10.1186/s13075-019-2073-x
   PubMed Web of Science ®Google Scholar
• Scarneo SA, Hughes PF, Yang KW, et al. A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase. J Biol Chem. 2020;295(6):1565–1574. doi:10.1074/jbc.RA119.011857
   PubMed Web of Science ®Google Scholar
• Totzke J, Scarneo SA, Yang KW, Haystead TAJ. TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases. Open Biol. 2020;10(9):200099. doi:10.1098/rsob.200099
   PubMed Web of Science ®Google Scholar
• Scarneo S, Zhang X, Wang Y, et al. Transforming Growth Factor-beta-Activated Kinase 1 (TAK1) mediates chronic pain and cytokine production in mouse models of inflammatory, neuropathic, and primary pain. J Pain. 2023;24(9):1633–1644. doi:10.1016/j.jpain.2023.04.011
   PubMedGoogle Scholar
• Katsura H, Obata K, Miyoshi K, et al. Transforming growth factor-activated kinase 1 induced in spinal astrocytes contributes to mechanical hypersensitivity after nerve injury. Glia. 2008;56(7):723–733. doi:10.1002/glia.20648
   PubMed Web of Science ®Google Scholar
• Goldmann T, Wieghofer P, Müller PF, et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci. 2013;16(11):1618–1626. doi:10.1038/nn.3531
   PubMed Web of Science ®Google Scholar
• Soto-Diaz K, Juda MB, Blackmore S, Walsh C, Steelman AJ. TAK1 inhibition in mouse astrocyte cultures ameliorates cytokine-induced chemokine production and neutrophil migration. J Neurochem. 2020;152(6):697–709. doi:10.1111/jnc.14930
   PubMed Web of Science ®Google Scholar
• Totzke J, Gurbani D, Raphemot R, et al. Takinib, a selective TAK1 inhibitor, broadens the therapeutic efficacy of TNF-alpha inhibition for cancer and autoimmune disease. Cell Chem Biol. 2017;24(8):1029–1039e1027. doi:10.1016/j.chembiol.2017.07.011
   PubMed Web of Science ®Google Scholar
• Scarneo S, Hughes P, Freeze R, et al. Development and efficacy of an orally bioavailable selective TAK1 inhibitor for the treatment of inflammatory arthritis. ACS Chem Biol. 2022;17(3):536–544. doi:10.1021/acschembio.1c00788
   PubMed Web of Science ®Google Scholar
• Christiansen CL, Stevens-Lapsley JE. Weight-bearing asymmetry in relation to measures of impairment and functional mobility for people with knee osteoarthritis. Arch Phys Med Rehabil. 2010;91(10):1524–1528. doi:10.1016/j.apmr.2010.07.009
   PubMed Web of Science ®Google Scholar
• Garsden LR, Bullock-Saxton JE. Joint reposition sense in subjects with unilateral osteoarthritis of the knee. Clin Rehabil. 1999;13(2):148–155. doi:10.1191/026921599674996411
   PubMed Web of Science ®Google Scholar
• Freeze R, Yang KW, Haystead T, Hughes P, Scarneo S. Delineation of the distinct inflammatory signaling roles of TAK1 and JAK1/3 in the CIA model of rheumatoid arthritis. Pharmacol Res Perspect. 2023;11(4):e01124. doi:10.1002/prp2.1124
   PubMed Web of Science ®Google Scholar
• Schlesinger N. Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy. Semin Arthritis Rheum. 2012;42(2):155–165. doi:10.1016/j.semarthrit.2012.03.010
   PubMed Web of Science ®Google Scholar
• Pitcher T, Sousa-Valente J, Malcangio M. The monoiodoacetate model of osteoarthritis pain in the mouse. J Vis Exp. 2016;(111). doi:10.3791/53746-v
   PubMed Web of Science ®Google Scholar
• Zheng S, Ren J, Gong S, Qiao F, He J. CTRP9 protects against MIA-induced inflammation and knee cartilage damage by deactivating the MAPK/NF-kappaB pathway in rats with osteoarthritis. Open Life Sci. 2020;15(1):971–980. doi:10.1515/biol-2020-0105
   PubMed Web of Science ®Google Scholar
• Liu P, Okun A, Ren J, et al. Ongoing pain in the MIA model of osteoarthritis. Neurosci Lett. 2011;493(3):72–75. doi:10.1016/j.neulet.2011.01.027
   PubMed Web of Science ®Google Scholar
• Yoshioka NK, Young GM, Khajuria DK, et al. Structural changes in the collagen network of joint tissues in late stages of murine OA. Sci Rep. 2022;12(1):9159. doi:10.1038/s41598-022-13062-y
   PubMed Web of Science ®Google Scholar
• Aoyagi K, Liew JW, Farrar JT, et al. Does weight-bearing versus non-weight-bearing pain reflect different pain mechanisms in knee osteoarthritis?: the Multicenter Osteoarthritis Study (MOST). Osteoarthritis Cartilage. 2022;30(4):545–550. doi:10.1016/j.joca.2021.10.014
   PubMed Web of Science ®Google Scholar
• Holden MA, Metcalf B, Lawford BJ, et al.; An international consensus study from the OARSI Rehabilitation Discussion Group. Recommendations for the delivery of therapeutic exercise for people with knee and/or Hip osteoarthritis. Osteoarthritis Cartilage. 2023;31(3):386–396. doi:10.1016/j.joca.2022.10.009
   PubMed Web of Science ®Google Scholar
• Bennell KL, Lawford BJ, Keating C, et al. Comparing video-based, telehealth-delivered exercise and weight loss programs with online education on outcomes of knee osteoarthritis: a randomized trial. Ann Intern Med. 2022;175(2):198–209. doi:10.7326/M21-2388
   PubMed Web of Science ®Google Scholar
• Biancuzzi H, Dal Mas F, Brescia V, et al. Opioid misuse: a review of the main issues, challenges, and strategies. Int J Environ Res Public Health. 2022;19(18):11754. doi:10.3390/ijerph191811754
   PubMed Web of Science ®Google Scholar
• Bale S, Verma P, Yalavarthi B, et al. Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis. JCI Insight. 2023;8(14). doi:10.1172/jci.insight.165358
   PubMed Web of Science ®Google Scholar